URL: http://www.leukemia-net.org/content/e58/e495/e501/index_eng.html

ELN

Leukemias

CML

Contact ·

Contact Persons in Project 4: Chronic myeloblastic leukemia (CML)

Created by: Hellenbrecht (ELIC) , generated 2006/03/14, last changed: 2008/06/04

Name	Initials	Clinic	Country
Lead Participants
M. Baccarani	BAC	Universitá di Bologna- Unita Complessa di Istituti di Cardiologia ed Ematologia	Italy
F. Guilhot	GUI	Université de Poitiers	France
R. Hehlmann	HEH	Ruprecht-Karls-Universität	Germany
A. Hochhaus	HOC	Ruprecht-Karls-Universität	Germany
B. Simonsson	SIM	Uppsala Universitet	Sweden
Participants
E. Abruzzese *	ABRU		Italy
J. Apperley	APP		UK
G. Baerlocher	BAE		Switzerland
M. Boogaerts	BOO	Katholieke Universiteit	Belgium
D. Boskovic	BOSK
T. Brümmendorf		Universitätsklinikum Hamburg Eppendorf	Germany
H. Bumbea	BUM		Romania
J. Cermak	CER		Czech Republic
F. Cervantes	CER	12 Hospital Clinic Provincial de Barcelona	Spain
R. Clark	CLA		UK
N.D. Colita	NCOL		Romania
A. Colita	COL	Fundeni Clinical Institute
J.J. Cornelissen	CORN	Erasmus University Medical Center	Netherlands
P. Costeas	COS
N.C.P. Cross	CRO		UK
L. Dusek	DUS		Czech Republic
J. Duyster	DUY		Germany
E. Faber	FAB		Czech Republic
W. Fiedler	FIE		Germany
T. Fischer	FIS	Johannes Gutenberg-Universität	Germany
C. Gambacorti-Passerini	GAP		Italy
J.M. Goldman	GOL	Imperial College	UK
A. Gratwohl	GRA	University of Basel/University Hospitals	Switzerland
J. Guilhot	GUIJ		France
J. Hasford	HAS	Ludwig-Maximilians-Universität	Germany
I.C. Haznedaroglu	HAZ	Ankara University	Turkey
A. Hellmann	HELL	Medical University of Gdansk	Poland
H. Hjorth-Hansen	HJO
K. Indrak	IND		Czech Republic
T. Lange	LAN		Germany
A. Levitzki	LEV		Israel
A. Lupu	LUP		Romania
F.X. Mahon	MAHO	Université Victor Segalen	France
G. Martinelli	MARG	Universitá di Bologna	Italy
J. Mayer	MAY	Fakultni nemocnice Brno	Czech Republic
M. Müller	MUE		Germany
J.L. Nielsen	NIE	Aarhus University Hospital	Denmark
S.G. O'Brien	OBR	University of Newcastle upon Tyne	UK
M.E. O'Dwyer	ODW	National University of Ireland	Ireland
G. Ossenkoppele	OSS		Netherlands
F. Pane	PAN		Italy
M. Pfirrmann	PFI		Germany
K. Porkka	POR		Finland
W. Prejzner	PREJ		Poland
R. Reuven	REUV		Israel
G. Rosti	ROS		Italy
T. Sacha	SACH		Poland
G. Saglio	SAG	Universitá degli Studi di Torino	Italy
S. Saußele *	SA		Germany
B. Skotnicki	SKO	Jagiellonian University, Medical College	Poland
J.-L. Steegmann	STE	Hospital Universitario de la Princesa	Spain
J. Thaler	THA	Klinikum Kreuzschwestern Wels GmbH	Austria
A. Tobler	TOBA	University of Bern	Switzerland
A. Turkina	TUR		Russia
G. Verhoef	VER	Katholieke Universiteit	Belgium
A.-M. Vladareanu	VLA		Romania
D. Zackova	ZAC		Czech Republic
A. Zaritskey	ZAR		Russia
* = Female Researcher

Lead Participants:

Prof.Dr. M. Baccarani (Bologna, Italy): Chairman of the Italian Cooperative Study Group on CML, which has been continuously active for more than 25 years and has run a number of clinical studies and trials which have been published in peer-reviewed journals, including chemotherapy, conventional and non conventional, splenectomy, interferon, autologous and allogeneic stem cell transplantation, interferon and low dose arabinosyl cytosine and imatinib. Prof. Baccarani has an international reputation for long term studies on treatment and prognosis of CML.

F. Guilhot (Poitiers, France): President of the French CML-Study Group. International recognition for his long term studies on Interferon-alpha alone and in combination with AraC in CML.

Prof.Dr. R. Hehlmann (Heidelberg, Germany): see Network Coordinator

PD Dr. A. Hochhaus (Heidelberg, Germany): Klinikum Mannheim of the University of Heidelberg. International recognition for his work on imatinib resistance and detection of minimal residual disease in CML. Conduction of phase I/II trials investigating new drugs and drug combinations in CML. Co-Lead of the German Competence Network “Acute and chronic leukemias”.

Prof.Dr. B. Simonsson (Uppsala, Sweden): Head Dept Hematology. Chairman of the Scandinavian CML-Study Group. International reputation for treatment intensification and autologous and allogeneic stem cell transplantation in CML.

Participants:

E. Abruzzese (, Italy):

J. Apperley (, UK):

G. Baerlocher (, Switzerland):

Prof.Dr. M. Boogaerts (Leuven, Belgium):

D. Boskovic (, ):

PD Dr. T. Brümmendorf (Hamburg, Germany):

H. Bumbea (, Romania):

J. Cermak (, Czech Republic):

Prof.Dr. F. Cervantes (Barcelona, Spain): Associate Professor, Hematology Department, University of Barcelona. Co-founder and member of the Writing Committee of the International CGL Prognosis Study Group. Member of the International Workshop on Myeloproliferative Diseases. Member of the Writing Committee of the group “International Collaboration on Transplantation in Agnogenic Metaplasia with Myelofibrosis”.

R. Clark (, UK):

N.D. Colita (, Romania):

Prof.Dr. A. Colita (Bucarest, ): Director of the Department of Hematology, University of Medicine.

Dr. J.J. Cornelissen (Rotterdam, Netherlands): Coordinator of the Dutch CML-Group.

P. Costeas (, ):

N.C.P. Cross (, UK):

L. Dusek (, Czech Republic):

J. Duyster (, Germany):

E. Faber (, Czech Republic):

W. Fiedler (, Germany):

PD Dr. T. Fischer (Mainz, Germany): The applicant is actively pursuing clinical and molecular research using selective tyrosine kinase inhibitors in hematologic and oncologic malignancies. A variety of early phase II protocols were initiated and combine molecular endpoints with clinical endpoints. This approach will define molecular criteria of sensitive patient populations and will provide important information for the design of future clinical trials using molecularly targeted therapies.

C. Gambacorti-Passerini (, Italy):

Prof.Dr. J.M. Goldman (London, UK): Chairman of the Department of Hematology, Hammersmith Hospital, Imperial College London. Original demonstration of stem cells in the blood of CML patients. Longstanding experience with allogeneic and autologous stem cell transplantation for CML. Pioneer in treating relapse after allografting with donor lymphocytes. The prognostic value of MRD monitoring for the BCR-ABL fusion transcript by competitive RT-PCR assays following allogeneic stem cell transplantation or therapy with IFN was developed in his lab. Former President of ISEH, EBMT and EHA. Editor of Bone Marrow Transplantation. Member of the Editorial Boards of several leading journals in hematology.

Prof.Dr. A. Gratwohl (Basel, Switzerland): Longstanding experience in clinical and experimental hematopoetic stem cell transplantation (HSCT). Former President of EBMT. Member of the acute and chronic leukemia WP of EBMT. Board member of EHA. Chair or Co-Chair of several prospective randomised studies in the field of HSCT. Responsible for co-ordinating retrospective risk factor analyses and prospective studies. Director of the EBMT activity surveys on incidence of HSCT in Europe and trend analyses.

J. Guilhot (, France):

Prof.Dr. J. Hasford (Munich, Germany):

Dr. I.C. Haznedaroglu (Ankara, Turkey): Coordinator of the Turkish CML Study Group.

Prof.Dr. A. Hellmann (Gdansk, Poland): Department of Hematology, Medical University of Gdansk. Referring center for diagnosis and treatment of CML patients for Northern Poland. Expertise includes modern treatment of CML (including allogeneic transplantation) with assessment of minimal residual disease utilizing classical cytogenetic studies, FISH and molecular monitoring of bcr/abl transcript. The current clinical research projects involve application of Glivec followed by BMT for patients in blast crisis and studies of molecular mechanism of Glivec resistance.

H. Hjorth-Hansen (, ):

K. Indrak (, Czech Republic):

T. Lange (, Germany):

A. Levitzki (, Israel):

A. Lupu (, Romania):

Dr. F.X. Mahon (Bordeaux, France): Longstanding experience in clinical and experimental research on CML. Co-worker of Prof. Reiffers, who is responsible for prospective studies on CML in France. The Bordeaux center was choosen as one of the five pilot centers in France for the JACIE accreditation.

G. Martinelli (Bologna, Italy):

Prof.Dr. J. Mayer (Brno, Czech Republic): Dept. of Internal Medicine –Hematooncology, University Hospital Brno. Associate Professor, Medical School, Masaryk´s University, Brno. Deputy Head of the Dept. Head of the Bone Marrow Transplantation and Leukemia Programs. Dept. of Internal Medicine 2 -Hematooncology, University Hospital Brno.

M. Müller (, Germany):

Prof.Dr. J.L. Nielsen (Aarhus, Denmark): Chairman of the Danish CML-Group.

Dr. S.G. O'Brien (Newcastle, UK): Consultant in Hematology. Main interests: Set up of randomized trials in CML including imatinib and imatinib-based therapies.

Prof.Dr. M.E. O'Dwyer (Galway, Ireland): Consultant Hematologist, University College Hospital Galway. Formerly Assistant Professor, Leukemia Center, Oregon Health & Science University under mentorship of Brian Druker. Co- investigator in all phase II and III licensing trials of imatinib in treatment of CML. Lead investiagtor of phase I/II study of imatinib in combination with interferon-alpha in chronic phase CML patients. Involved in development of other new combination protocols using imatinib and other novel agents.

Prof.Dr. G. Ossenkoppele (, Netherlands):

F. Pane (, Italy):

M. Pfirrmann (, Germany):

K. Porkka (, Finland):

W. Prejzner (, Poland):

R. Reuven (, Israel):

G. Rosti (, Italy):

T. Sacha (, Poland):

Prof.Dr. G. Saglio (Turin, Italy): Professor in Internal Medicine and Hematology.

Dr. S. Saußele (, Germany):

Prof.Dr. B. Skotnicki (Krakow, Poland): Coordinator of the Polish CML group.

Prof.Dr. J.-L. Steegmann (Madrid, Spain): Coordinator of the Spanish CML Group GELMC.

Prof.Dr. J. Thaler (Wels, Austria): Chairman of the Department of Internal Medicine IV, General Hospital Wels, Austria. Coordinator of the studies 4-9 of the Austrian CML study group since 1990 and of the Central European CML Study Group (CELSG) since 1999.

Prof.Dr. A. Tobler (Bern, Switzerland): He has been involved for many years in clinical studies in chronic myeloid leukemia within the framework of the German CML-Study group and the SAKK. He also is active in experimental hematology research with the focus on molecular studies in normal and leukemic hematopoiesis with particular emphasis on allelotyping in lymphoid neoplasms, myeloid differentiation and cell cycle. Current studies aim at elucidating the regulation of the apoptotic and antiapoptotic p73 gene in the various phases of CML and its regulation by imatinib. His research is funded by a grant of the Swiss National Science Foundation and several other grants.

A. Turkina (, Russia):

Prof.Dr. G. Verhoef (Leuven, Belgium): Coordinator of the Belgian CML group for imatinib studies.

A.-M. Vladareanu (, Romania):

D. Zackova (, Czech Republic):

A. Zaritskey (, Russia):